Servier’s ASCO 2025 data: Advancing IDH-mutated cancer treat...

At ASCO 2025, Servier’s Becky Martin discusses IDH-mutated cancers, including key insights on Tibsovo & Voranigo, and the implications for patients.

Breaking barriers to CAR T-cell therapy: The vision for expa...

Live from ASCO 2025: Prof. Dr Jason Westin discusses CAR-T Vision, patient access, and the push to expand therapy reach in rare blood cancers.

Live from ASCO 2025: Boehringer Ingelheim on unmet needs and...

Regeneron at ASCO 25: Advancing multiple myeloma treatment